Background: Many prognostic biomarkers associated with androgen signaling have been proposed in PC. The role of tripartite motif (TRIM) proteins remains unclear in PC. We investigated TRIM protein 47 (TRIM47) expression levels in human prostate tissues.
Methods: We performed immunohistochemistry using original TRIM47 antibody in prostate tissues obtained by radical prostatectomy (n = 105). Stained slides were evaluated for the proportion and staining intensity of immunoreactive cells. Total immunoreactivity (IR) scores (range, 0-8) were calculated as the sum of the proportion and intensity scores. TRIM47 expression levels were confirmed by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Associations between the clinicopathologic features of the patients and their TRIM47 status were analyzed.
Results: Western blot analysis validated the specificity of the anti-TRIM47 antibody in 293T cells. TRIM47 expression levels were found to be significantly increased in PC compared to benign tissues by both immunohistochemistry (P < .0001) and qRT-PCR (P = .003). Additionally, advanced pathologic stage (≥ T3b) was found to be associated with high TRIM47 IR scores (≥ 4; P = .04). Furthermore, high TRIM47 IR scores were also significantly correlated with worse cancer-specific survival rates in multivariate regression analyses (hazard ratio, 6.82; P = .016).
Conclusion: The results of the present study indicated differential TRIM47 expression levels in human prostate tissues compared to benign tissues. Because high levels of TRIM47 expression were found to be a strong prognostic factor in PC, TRIM47 may represent a novel therapeutic target.
Keywords: Prognosis; Prostate cancer; Survival; TRIM; Tripartite motif.
Copyright © 2016 Elsevier Inc. All rights reserved.